The deal, which will focus first on a COPD therapy GSK believes holds “best-in-class” potential, could ultimately involve a ...

Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new ...

Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several ...

The two companies have entered into an agreement to develop respiratory, immunology, inflammation, and cancer therapies.

The deal comes as GSK, led by chief exec Emma Walmsley (pictured) focuses on growing its pipeline to offset declining ...

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

GSK plc has entered into agreements with China-based biotechnology company Hengrui Pharma to develop up to 12 innovative ...

The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...

Jiangsu Hengrui Pharmaceuticals shares rallied to their highest level in four years – leaping 10% to 62.04 renminbi - after ...

GSK has entered into a partnership with Chinese pharmaceutical outfit Hengrui Pharma to jointly develop up to 12 medicines, ...